Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors
Aura Biosciences (NASDAQ: AURA) has appointed Teresa Bitetti to its Board of Directors, effective March 31, 2025. Bitetti currently serves as President of the Global Oncology Business Unit at Takeda, where she manages a multi-billion-dollar oncology portfolio across major markets including the US, Europe, and Japan.
As a seasoned executive, Bitetti brings extensive operational and commercial experience from her previous roles, including Senior Vice President positions at Bristol Myers Squibb (BMS) where she led worldwide oncology commercialization and headed U.S. Oncology operations. Her expertise spans multiple therapeutic areas including infectious diseases and neuroscience.
The appointment aligns with Aura's focus on developing precision therapies for solid tumors while preserving organ function, particularly in ocular and urologic oncology.
Aura Biosciences (NASDAQ: AURA) ha nominato Teresa Bitetti nel suo Consiglio di Amministrazione, con effetto dal 31 marzo 2025. Bitetti attualmente ricopre il ruolo di Presidente della Global Oncology Business Unit presso Takeda, dove gestisce un portafoglio oncologico da miliardi di dollari in mercati principali come Stati Uniti, Europa e Giappone.
Come dirigente esperta, Bitetti porta con sé un'ampia esperienza operativa e commerciale derivante dai suoi ruoli precedenti, tra cui quello di Vicepresidente Senior presso Bristol Myers Squibb (BMS), dove ha guidato la commercializzazione oncologica a livello mondiale e ha diretto le operazioni oncologiche negli Stati Uniti. La sua esperienza copre diverse aree terapeutiche, comprese le malattie infettive e le neuroscienze.
Questa nomina è in linea con l'obiettivo di Aura di sviluppare terapie di precisione per i tumori solidi, preservando la funzione degli organi, in particolare nell'oncologia oculare e urologica.
Aura Biosciences (NASDAQ: AURA) ha nombrado a Teresa Bitetti en su Junta Directiva, con efecto a partir del 31 de marzo de 2025. Bitetti actualmente ocupa el cargo de Presidenta de la Unidad de Negocios de Oncología Global en Takeda, donde gestiona un portafolio oncológico de miles de millones de dólares en mercados clave, incluidos EE. UU., Europa y Japón.
Como ejecutiva experimentada, Bitetti aporta una amplia experiencia operativa y comercial de sus roles anteriores, incluyendo posiciones de Vicepresidenta Senior en Bristol Myers Squibb (BMS), donde lideró la comercialización oncológica a nivel mundial y dirigió las operaciones de Oncología en EE. UU. Su experiencia abarca múltiples áreas terapéuticas, incluidas las enfermedades infecciosas y la neurociencia.
El nombramiento está alineado con el enfoque de Aura en desarrollar terapias de precisión para tumores sólidos, preservando la función orgánica, particularmente en oncología ocular y urológica.
아우라 바이오사이언스 (NASDAQ: AURA)는 2025년 3월 31일부로 테레사 비테티를 이사회에 임명했습니다. 비테티는 현재 다케다의 글로벌 종양학 사업부의 사장으로 재직하며 미국, 유럽, 일본을 포함한 주요 시장에서 수십억 달러 규모의 종양학 포트폴리오를 관리하고 있습니다.
경험이 풍부한 임원으로서 비테티는 브리스톨 마이어스 스퀴브(BMS)에서 선임 부사장으로 근무하며 전 세계 종양학 상업화를 이끌고 미국 종양학 운영을 책임지는 등 폭넓은 운영 및 상업 경험을 제공합니다. 그녀의 전문 분야는 감염병 및 신경과학을 포함한 여러 치료 영역에 걸쳐 있습니다.
이번 임명은 아우라가 장기 종양에 대한 정밀 치료를 개발하면서 장기 기능을 보존하는 데 중점을 두고 있다는 점과 일치합니다. 특히 안과 및 비뇨기 종양학 분야에서 그렇습니다.
Aura Biosciences (NASDAQ: AURA) a nommé Teresa Bitetti au sein de son Conseil d'Administration, avec effet au 31 mars 2025. Bitetti occupe actuellement le poste de Présidente de l'Unité Commerciale Oncologique Mondiale chez Takeda, où elle gère un portefeuille oncologique de plusieurs milliards de dollars sur des marchés majeurs tels que les États-Unis, l'Europe et le Japon.
En tant que cadre expérimentée, Bitetti apporte une vaste expérience opérationnelle et commerciale de ses précédents postes, y compris celui de Vice-Présidente Senior chez Bristol Myers Squibb (BMS), où elle a dirigé la commercialisation mondiale de l'oncologie et supervisé les opérations oncologiques aux États-Unis. Son expertise couvre plusieurs domaines thérapeutiques, y compris les maladies infectieuses et les neurosciences.
Cette nomination s'inscrit dans l'objectif d'Aura de développer des thérapies de précision pour les tumeurs solides tout en préservant la fonction des organes, en particulier dans le domaine de l'oncologie oculaire et urologique.
Aura Biosciences (NASDAQ: AURA) hat Teresa Bitetti mit Wirkung zum 31. März 2025 in seinen Vorstand berufen. Bitetti ist derzeit Präsidentin der Global Oncology Business Unit bei Takeda, wo sie ein milliardenschweres Onkologie-Portfolio in wichtigen Märkten wie den USA, Europa und Japan verwaltet.
Als erfahrene Führungskraft bringt Bitetti umfangreiche operative und kommerzielle Erfahrungen aus ihren früheren Positionen mit, darunter die Rolle der Senior Vice President bei Bristol Myers Squibb (BMS), wo sie die weltweite Onkologie-Kommerzialisierung leitete und die US-Onkologie-Operationen verantwortete. Ihre Expertise erstreckt sich über mehrere therapeutische Bereiche, einschließlich Infektionskrankheiten und Neurowissenschaften.
Die Ernennung steht im Einklang mit dem Fokus von Aura, präzise Therapien für solide Tumoren zu entwickeln, während die Organfunktion, insbesondere in der Augen- und Urologie-Onkologie, erhalten bleibt.
- Addition of experienced commercial oncology executive to Board of Directors
- New director brings expertise in global markets (US, Europe, Japan)
- Strategic appointment aligns with company's oncology focus
- None.
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company’s Board of Directors, effective March 31, 2025.
“I am pleased to welcome Teresa to our Board of Directors,” said Elisabet de los Pinos, Chief Executive Officer of Aura Biosciences. “She is a seasoned leader whose extensive operational and commercial experience will be instrumental as we advance our clinical pipeline across ocular and urologic oncology.”
“I am excited to join Aura’s Board of Directors as the Company works to develop novel therapies in areas of high unmet medical need,” said Ms. Bitetti. “I look forward to collaborating with the Aura team as they continue to grow as an innovative global oncology company and work to fulfill their mission of transforming patients’ lives.”
Ms. Bitetti is currently the President of the Global Oncology Business Unit and a member of the Executive Team at Takeda, where she oversees a global portfolio of therapies targeting gastrointestinal, thoracic, and hematological cancers. In this role, Ms. Bitetti leads all aspects of Takeda’s multi-billion-dollar oncology business, with major markets in the US, Europe, and Japan. Before joining Takeda, Ms. Bitetti was Senior Vice President and Head of Worldwide Oncology Commercialization at Bristol Myers Squibb (BMS). She held leadership roles of increasing responsibility at BMS, including in infectious diseases and neuroscience. She served as Senior Vice President and Head of U.S. Oncology, President and General Manager of BMS Canada, and Worldwide Head of BMS Virology. Prior to BMS, Ms. Bitetti was part of the Capital Markets Group at Mobil Oil Corporation, overseeing the investment of Mobil’s worldwide pension assets. In addition to her role at Takeda, Ms. Bitetti serves on the Board of Directors for Osmol Therapeutics, which is focused on developing a treatment to prevent chemotherapy-induced peripheral neuropathy. Ms. Bitetti earned her MBA from the Darden School of Business at the University of Virginia and her BA from Wellesley College.
About Aura Biosciences
Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA. Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients. For more information, visit aurabiosciences.com. Follow us on X (formerly Twitter) @AuraBiosciences and visit us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “may,” “will,” “could,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “endeavor,” “potential,” “continue” or the negative of such words or other similar expressions can be used to identify forward-looking statements. These forward-looking statements include express or implied statements regarding Aura’s future expectations, plans and prospects, including, without limitation, statements regarding the therapeutic potential of bel-sar for the treatment of multiple cancers; statements regarding Aura’s plans and expectations for its ongoing and future clinical trials of bel-sar in multiple oncology indications; statements regarding Aura’s plans to advance its clinical pipeline; statements regarding achieving Aura’s goal to transform patients’ lives; and statements regarding Aura’s expectations for the estimated patient populations and related market opportunities for bel-sar.
The forward-looking statements in this press release are neither promises nor guarantees, and investors should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Aura’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, without limitation, uncertainties inherent in clinical trials and in the availability and timing of data from ongoing clinical trials; the expected timing for submissions for regulatory approval or review by governmental authorities; the risk that the results of Aura’s preclinical and clinical trials may not be predictive of future results in connection with future clinical trials; the risk that early or interim data from ongoing clinical trials may not be predictive of final data from completed clinical trials; the risk that governmental authorities may disagree with Aura’s clinical trial designs, even where Aura has obtained agreement with governmental authorities on the design of such trials, such as the Phase 3 special protocol assessment agreement with the U.S. Food and Drug Administration; whether Aura will receive regulatory approvals to conduct trials or to market products; whether Aura’s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; Aura’s ongoing and planned preclinical activities; and Aura’s ability to initiate, enroll, conduct or complete ongoing and planned clinical trials. These risks, uncertainties and other factors include those risks and uncertainties described under the heading “Risk Factors” in Aura’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the United States Securities and Exchange Commission (SEC) and in subsequent filings made by Aura with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Aura disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Aura’s current expectations and speak only as of the date hereof and no representations or warranties (express or implied) are made about the accuracy of any such forward-looking statements.
Investor and Media Contact:
Alex Dasalla
Head of Investor Relations and Corporate Communications
IR@aurabiosciences.com
FAQ
When did Teresa Bitetti join AURA's Board of Directors?
What is Teresa Bitetti's current role outside of AURA?
What therapeutic areas is AURA focusing on developing treatments for?
What was Teresa Bitetti's previous experience before joining Takeda?
